Brolucizumab for treating diabetic macular oedema

Equality Impact Assessment (Guidance development) (PDF 141 KB)

Register of interests (PDF 171 KB)

Final draft guidance

Final appraisal document (PDF 180 KB)

Committee papers (PDF 2.59 MB)

Final scope (PDF 206 KB)

Final stakeholder list (PDF 185 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 357 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Draft scope post referral (PDF 218 KB)

Draft matrix post referral (PDF 189 KB)